Clinical Trials Logo

Multiple System Atrophy (MSA) clinical trials

View clinical trials related to Multiple System Atrophy (MSA).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06204575 Completed - Clinical trials for Dementia With Lewy Bodies

Focused Ultrasound Thalamotomy for Tremor Relief in Atypical Parkinsonism

FUSAP
Start date: November 1, 2013
Phase:
Study type: Observational

The goal of this retrospective observational study is to describe the efficacy of focused ultrasound ventral-intermediate nucleus thalamotomy in patients with atypical parkinsonism. - Is this treatment efficacious in patients with multiple system atrophy? - Is this treatment efficacious in patients with diffuse Lewy Body Dementia? Data will be collected from patients charts.

NCT ID: NCT04193527 Completed - Essential Tremor Clinical Trials

A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients

Start date: June 28, 2020
Phase: Phase 3
Study type: Interventional

This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical diagnosis of Parkinsonian syndrome (PS) involving striatal dopaminergic deficit (SDD; specifically, Parkinson's disease [PD] [SDD], multiple system atrophy [MSA] [SDD] or or progressive supranuclear palsy [PSP] [SDD]) as compared with patients with a clinical diagnosis of essential tremor (ET) (no SDD) and age-matched healthy controls.

NCT ID: NCT02796209 Completed - Clinical trials for Multiple System Atrophy (MSA)

Norepinephrine Transporter Blockade, Autonomic Failure

Start date: May 2016
Phase: Phase 2
Study type: Interventional

Atomoxetine, a selective norepinephrine transporter (NET) blocker, increases standing blood pressure and improves neurogenic orthostatic hypotension (NOH)-related symptoms to a greater extent than midodrine, the current standard of care. Atomoxetine could be a new therapeutic alternative for the treatment of NOH in patients with autonomic failure, particularly those with multiple system atrophy (MSA). The proposed study consists of an open-label, dose-optimization phase followed by a randomized, double-blind, placebo-controlled, 2x2 crossover phase.

NCT ID: NCT02388295 Completed - Clinical trials for Multiple System Atrophy, MSA

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Start date: April 27, 2015
Phase: Phase 2
Study type: Interventional

AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.

NCT ID: NCT01888185 Completed - Parkinsonism Clinical Trials

Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)

Start date: December 2012
Phase:
Study type: Observational

This study is designed to determine if magnetic resonance imaging (MRI) measures can be used to diagnose and monitor the progression of Parkinson's disease (PD) while distinguishing between PD and parkinsonisms [conditions that are PD look-a-like diseases such as progressive supranuclear palsy (PSP) or multiple system atrophy (MSA)] when combined with changes in certain proteins in body fluids that are related to iron (Fe).

NCT ID: NCT01485549 Completed - Clinical trials for Multiple System Atrophy (MSA)

Oligomeric Alpha-synuclein in Multiple System Atrophy

BIOAMS
Start date: November 26, 2012
Phase:
Study type: Observational

The main objectives are to determine on one hand whether oligomeric alpha-synuclein levels are increased in MSA patients compared to controls and on other hand whether there is a good agreement between cerebrospinal fluid (CSF) and plasma levels.